UY32317A - Anticuerpos anti-igf - Google Patents

Anticuerpos anti-igf

Info

Publication number
UY32317A
UY32317A UY0001032317A UY32317A UY32317A UY 32317 A UY32317 A UY 32317A UY 0001032317 A UY0001032317 A UY 0001032317A UY 32317 A UY32317 A UY 32317A UY 32317 A UY32317 A UY 32317A
Authority
UY
Uruguay
Prior art keywords
igf
antibodies
insulin
bind
receptor
Prior art date
Application number
UY0001032317A
Other languages
English (en)
Inventor
Borges Eric
Adam Paul
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512371&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32317(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY32317A publication Critical patent/UY32317A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Moléculas de anticuerpos, en particular anticuerpos completamente de ser humano que se unen a IGF-1 de ser humano y que tienen reactividad cruzada con IGF-2 tal que se impide la unión de IGF-1 e IGF-2 al receptor de IGF-1 y se inhibe la transmisión de señales mediada por el receptor de IGF-1. Los anticuerpos no se unen a la insulina y de este modo no afectan a las propiedades mitogénicas de la insulina que son mediadas por su enlace a los receptores de la insulina. Los anticuerpos son útiles para el tratamiento de enfermedades hiperproliferativas, en particular el cáncer.
UY0001032317A 2008-12-12 2009-12-11 Anticuerpos anti-igf UY32317A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08171554 2008-12-12

Publications (1)

Publication Number Publication Date
UY32317A true UY32317A (es) 2010-07-30

Family

ID=40512371

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032317A UY32317A (es) 2008-12-12 2009-12-11 Anticuerpos anti-igf

Country Status (39)

Country Link
US (4) US8318159B2 (es)
EP (2) EP3064219A3 (es)
JP (2) JP5694184B2 (es)
KR (1) KR101827332B1 (es)
CN (3) CN103396487A (es)
AP (1) AP3371A (es)
AR (1) AR074726A1 (es)
AU (1) AU2009324296B2 (es)
BR (1) BRPI0923359B8 (es)
CA (1) CA2740341C (es)
CL (1) CL2011001431A1 (es)
CO (1) CO6390042A2 (es)
CY (1) CY1117241T1 (es)
DK (1) DK2376116T3 (es)
EA (1) EA029178B1 (es)
EC (1) ECSP11011126A (es)
ES (1) ES2561045T3 (es)
GE (1) GEP20146119B (es)
HK (1) HK1158933A1 (es)
HR (1) HRP20160190T1 (es)
HU (1) HUE026374T2 (es)
IL (1) IL212047A (es)
MA (1) MA32888B1 (es)
ME (1) ME02377B (es)
MX (1) MX2011006055A (es)
MY (1) MY150984A (es)
NZ (3) NZ597692A (es)
PE (1) PE20120415A1 (es)
PL (1) PL2376116T3 (es)
PT (1) PT2376116E (es)
RS (1) RS54423B1 (es)
SG (2) SG2014013841A (es)
SI (1) SI2376116T1 (es)
TN (1) TN2011000299A1 (es)
TW (1) TWI471139B (es)
UA (1) UA105198C2 (es)
UY (1) UY32317A (es)
WO (1) WO2010066868A2 (es)
ZA (1) ZA201102308B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02371B (me) * 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
PT2769729T (pt) 2007-09-04 2019-05-08 Compugen Ltd Polipéptidos e polinucleótidos, e utilizações dos mesmos como um alvo de fármacos para produzir fármacos e agentes biológicos
CN102232087A (zh) 2008-11-10 2011-11-02 诺瓦提斯公司 修饰的人igf-1/e肽的抗体
SI2376116T1 (sl) 2008-12-12 2016-03-31 Boehringer Ingelheim International Gmbh Anti-IGF protitelesa
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
EP2494070A2 (en) * 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
WO2012142164A1 (en) * 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
HRP20230078T1 (hr) 2011-09-23 2023-05-12 Mereo Biopharma 5, Inc. Sredstva za vezivanje vegf/dll4 i njihova uporaba
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
WO2013114367A2 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
TWI750197B (zh) * 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
CN102863530A (zh) * 2012-09-26 2013-01-09 李彬 一种脂肪细胞分化代谢产物igf-1抗体及包含该抗体的芯片以及应用
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
PL2992012T3 (pl) 2013-04-29 2019-12-31 F. Hoffmann-La Roche Ag Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania
US10508133B2 (en) * 2013-10-18 2019-12-17 Novasep Process Purification of proteins
US20160324962A1 (en) * 2013-12-19 2016-11-10 Medimmune, Llc Compositions and methods for treating sarcoma
EP3842455A1 (en) 2014-01-15 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with improved protein a-binding
RS59649B1 (sr) * 2014-01-24 2020-01-31 Boehringer Ingelheim Int Lečenje raka korišćenjem receptora antagoniste faktora rasta sličan insulinu (igf) u kombinaciji sa eksemestanom i everolimusom
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN107530419B (zh) 2014-10-31 2021-05-18 昂考梅德药品有限公司 治疗疾病的组合疗法
US20180104332A1 (en) * 2015-01-16 2018-04-19 The University Of Liverpool Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy
EP3341021A4 (en) * 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US20170088609A1 (en) 2015-09-28 2017-03-30 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CN105622730B (zh) * 2016-02-18 2020-06-26 深圳华尔康生物科技有限公司 一种特异性结合igf-1的多肽及其应用
EP3878850A1 (en) 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
CN111148534A (zh) 2017-09-29 2020-05-12 勃林格殷格翰国际有限公司 抗igf和抗pd-1抗癌组合疗法
JP7189956B2 (ja) 2017-12-21 2022-12-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｏｓ１阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体
KR102404684B1 (ko) * 2019-01-15 2022-06-07 서울대학교산학협력단 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물
WO2021245051A1 (en) 2020-06-02 2021-12-09 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CA3203111A1 (en) 2020-12-22 2022-06-30 Kailiang Wang Sos1 inhibitors and uses thereof
WO2022223033A1 (zh) 2021-04-23 2022-10-27 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202337431A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202340209A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
TW202337432A (zh) 2021-12-01 2023-10-01 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN114671949B (zh) * 2022-04-20 2023-04-28 山西农业大学 一种igf1纳米抗体及其应用
WO2023225657A2 (en) * 2022-05-20 2023-11-23 Rezolute, Inc. Formulations for anti-insulin receptor antibody and uses thereof
WO2024080509A1 (ko) * 2022-10-14 2024-04-18 포항공과대학교 산학협력단 Igf-1 수용체 결합 압타머 및 이의 용도

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
ATE220101T1 (de) 1983-04-25 2002-07-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinähnlichen wachstumsfaktoren
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
AU1232188A (en) 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
DE68908175T2 (de) 1988-05-27 1994-03-03 Centocor Inc Gefriergetrocknete formulierung für antikörperprodukte.
JPH03501487A (ja) 1988-06-30 1991-04-04 シティ・オブ・ホープ インシュリン模倣物およびインシュリンリセプター結合部位ペプチド
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
WO1994029347A1 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
WO1995025794A1 (fr) 1994-03-23 1995-09-28 Japan Clinical Laboratories Anticorps monoclonal anti-igf-i
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
ATE328903T1 (de) 1997-11-27 2006-06-15 Commw Scient Ind Res Org Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
MXPA01010891A (es) * 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
UY27087A1 (es) * 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
EP2706116A1 (en) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
ES2427964T3 (es) 2002-01-18 2013-11-05 Pierre Fabre Medicament Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
US7438911B2 (en) * 2002-04-30 2008-10-21 Kyowa Hakko Kogyo Co., Ltd. Antibody against human insulin-like growth factor
JP2003310275A (ja) 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd ヒトインスリン様成長因子に対する遺伝子組換え抗体
PL210412B1 (pl) 2002-05-24 2012-01-31 Schering Corp Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US20030138430A1 (en) * 2002-09-20 2003-07-24 Stimmel Julie Beth Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
KR20050109489A (ko) 2003-02-13 2005-11-21 화이자 프로덕츠 인크. 항-인슐린양 성장인자 ｉ 수용체 항체의 용도
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
WO2005018671A1 (ja) 2003-08-21 2005-03-03 Kyowa Hakko Kogyo Co., Ltd. 癌転移阻害剤
US7498415B2 (en) * 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
JPWO2005027970A1 (ja) 2003-09-24 2007-11-15 協和醗酵工業株式会社 癌治療用医薬
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
WO2006008639A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1888647A2 (en) 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
SG10201400973XA (en) 2005-10-12 2014-08-28 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
ES2385054T3 (es) * 2005-12-13 2012-07-17 Medimmune Limited Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
AP2008004569A0 (en) 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
EP1999149A4 (en) * 2006-03-28 2010-01-20 Biogen Idec Inc ANTI-IGF-1R ANTIBODIES AND USES THEREOF
EP2010567A2 (en) * 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Antibody compositions and methods for treatment of neoplastic disease
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
KR101467136B1 (ko) 2006-06-02 2014-12-01 화이자 프로덕츠 인코포레이티드 순환 종양 세포 분석
ATE537450T1 (de) 2006-06-30 2011-12-15 Schering Corp Igfbp2-biomarker
WO2008079324A1 (en) 2006-12-21 2008-07-03 Boston Biomedical Research Institute Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
GB0702888D0 (en) 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
EP2129397B1 (en) 2007-03-02 2018-10-31 Amgen, Inc. Methods and compositions for treating tumor diseases
WO2008115470A2 (en) 2007-03-16 2008-09-25 East Carolina University Hox-gene expression as a biomarker for igf-1r therapeutics
KR20090113340A (ko) 2007-03-22 2009-10-29 임클론 엘엘씨 안정한 항체 제제
EP2559771A3 (en) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
WO2008144720A2 (en) 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
WO2008152422A2 (en) 2007-06-12 2008-12-18 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof-909
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009006336A1 (en) 2007-06-28 2009-01-08 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
JP2010535710A (ja) 2007-07-31 2010-11-25 メルク・シャープ・エンド・ドーム・コーポレイション 細胞増殖性疾患の検出及び診断に有用なｉｇｆ−１ｒ特異抗体
CA2694055A1 (en) 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
EP2183275B1 (en) 2007-08-03 2014-10-29 Affibody AB Igf-1r binding polypeptides and their use
EP2952588A1 (en) 2007-08-06 2015-12-09 Orion Genomics, LLC Single nucleotide polymorphism in igf2 for determining the allele-specific expression of the igf2 gene
CN101842117A (zh) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 抗igf-1r抗体及其用途
WO2009032782A2 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
EP2193211A4 (en) 2007-09-19 2010-12-08 Univ Boston IDENTIFICATION OF NEW PATHWAYS FOR THE DEVELOPMENT OF MEDICINES FOR THE TREATMENT OF LUNG DISEASES
EP2201378A2 (en) 2007-10-03 2010-06-30 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8048621B2 (en) 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
MX2010006854A (es) 2007-12-18 2010-09-09 Schering Corp Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
US20090258365A1 (en) 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
CN102065895A (zh) 2008-04-11 2011-05-18 比奥根艾迪克Ma公司 抗-igf-1r抗体和其它化合物的治疗联合
CA2722992A1 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
WO2009137758A2 (en) 2008-05-09 2009-11-12 Dyax Corp. Igf-ii/gf-iie binding proteins
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN102224239A (zh) 2008-09-26 2011-10-19 先灵公司 高效价抗体生产
MX2011003133A (es) 2008-09-26 2011-04-21 Roche Glycart Ag Anticuerpos biespecificos anti-egfr/anti-igf-1r.
CA2740440A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
JP2012506238A (ja) 2008-10-20 2012-03-15 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト インスリン様増殖因子−１受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー
CN102232087A (zh) 2008-11-10 2011-11-02 诺瓦提斯公司 修饰的人igf-1/e肽的抗体
EP2350649A4 (en) 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
SI2376116T1 (sl) 2008-12-12 2016-03-31 Boehringer Ingelheim International Gmbh Anti-IGF protitelesa
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
EP2381774A4 (en) 2008-12-23 2012-07-18 Salk Inst For Biological Studi METHOD OF TREATING NEURODEGENERATIVE DISEASE
JP2012524087A (ja) 2009-04-16 2012-10-11 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｅｇｆｒ物質とｉｇｆ−１ｒ特異的インヒビターとを使用する組合せ療法
WO2011057064A1 (en) 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
WO2013148568A1 (en) 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
WO2013169611A1 (en) 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Compositions and methods for treating breast cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
RS59649B1 (sr) 2014-01-24 2020-01-31 Boehringer Ingelheim Int Lečenje raka korišćenjem receptora antagoniste faktora rasta sličan insulinu (igf) u kombinaciji sa eksemestanom i everolimusom
US20170088609A1 (en) 2015-09-28 2017-03-30 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Also Published As

Publication number Publication date
EA029178B1 (ru) 2018-02-28
UA105198C2 (ru) 2014-04-25
DK2376116T3 (en) 2016-02-29
CN103396488A (zh) 2013-11-20
EA201100918A1 (ru) 2012-01-30
EP3064219A3 (en) 2016-09-28
ECSP11011126A (es) 2011-07-29
TWI471139B (zh) 2015-02-01
CY1117241T1 (el) 2017-04-05
HRP20160190T1 (hr) 2016-03-25
BRPI0923359B8 (pt) 2021-05-25
SG2014013841A (en) 2014-07-30
US20150010574A1 (en) 2015-01-08
KR20110094034A (ko) 2011-08-19
TW201026327A (en) 2010-07-16
EP2376116A2 (en) 2011-10-19
JP5694184B2 (ja) 2015-04-01
BRPI0923359A2 (pt) 2015-07-21
TN2011000299A1 (en) 2012-12-17
SI2376116T1 (sl) 2016-03-31
PE20120415A1 (es) 2012-05-09
CO6390042A2 (es) 2012-02-29
CN102227226B (zh) 2015-05-13
US11299538B2 (en) 2022-04-12
EP2376116B1 (en) 2015-12-09
MA32888B1 (fr) 2011-12-01
KR101827332B1 (ko) 2018-02-09
CA2740341A1 (en) 2010-06-17
US20100150940A1 (en) 2010-06-17
ES2561045T3 (es) 2016-02-24
NZ597694A (en) 2013-08-30
AR074726A1 (es) 2011-02-09
NZ597692A (en) 2013-08-30
AP3371A (en) 2015-07-31
HK1158933A1 (en) 2012-07-27
MX2011006055A (es) 2011-07-04
JP2015131812A (ja) 2015-07-23
AU2009324296B2 (en) 2016-07-28
AP2011005719A0 (en) 2011-06-30
IL212047A0 (en) 2011-06-30
CL2011001431A1 (es) 2012-02-17
IL212047A (en) 2016-03-31
SG172107A1 (en) 2011-07-28
NZ592151A (en) 2012-10-26
PT2376116E (pt) 2016-02-24
RS54423B1 (en) 2016-04-28
ME02377B (me) 2016-06-20
AU2009324296A1 (en) 2010-06-17
GEP20146119B (en) 2014-07-25
ZA201102308B (en) 2011-12-28
EP3064219A2 (en) 2016-09-07
WO2010066868A3 (en) 2010-09-10
HUE026374T2 (en) 2016-05-30
US20190225681A1 (en) 2019-07-25
CA2740341C (en) 2019-05-07
CN103396487A (zh) 2013-11-20
WO2010066868A2 (en) 2010-06-17
MY150984A (en) 2014-03-31
US20130230541A1 (en) 2013-09-05
US10179810B2 (en) 2019-01-15
BRPI0923359B1 (pt) 2020-09-15
JP2012511315A (ja) 2012-05-24
PL2376116T3 (pl) 2016-07-29
US8318159B2 (en) 2012-11-27
CN102227226A (zh) 2011-10-26

Similar Documents

Publication Publication Date Title
ECSP11011126A (es) Anticuerpos anti-igf
UY31160A1 (es) Anticuerpos anti-igf
CR20150669A (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
AR068997A1 (es) Anticuerpos contra el vegf completamente humano y sus metodos de uso
MX2013000366A (es) Inmonoglubulinas de dominio variable doble y usos de las mismas.
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
AR074777A1 (es) Proteinas de union a antigeno
AR062895A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
EA033072B1 (ru) Применение антител к семафорину 4d для лечения болезни хантингтона
PA8849001A1 (es) Anticuerpos de c-met
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
NZ623264A (en) Sparc binding scfvs
DOP2013000219A (es) Anticuerpos imitadores de receptores de celulas t especificos para peptido wt1 unido a hla-a2
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.
NZ611428A (en) Novel modulators and methods of use
CO6690769A2 (es) Proteínas de unión a antígenos que se unen al receptor her3, polinucleótidos que los comdifican y composiciones que los contienen, útiles a el tratamiento o profilaxis de varios tipos de cancer
RS54627B1 (en) CANCER EXPRESSION ANTIBODIES THAT EXPLAIN CLAUDINE 6
CL2008001675A1 (es) Dominio variable simple (dab) de inmunoglobulina anti-factorde crecimiento endotelial vascular (vegf); acido nucleico que lo codifica; vector y celula huesped; metodo de produccion;antogonista de vegf que comprende el dab; composicion que comprende antogonista;y uso del antagonista para preparar un medicamento.
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
BR112014006822A2 (pt) proteínas de ligação ao antígeno cd27l
UY35016A (es) Moléculas de unión a il-18
CL2011000769A1 (es) Anticuerpo biespecifico que se une especificamente al factor de crecimiento endotelial vascular humano (vegf) y a la angiopoyetina-2 humana (ang-2); acido nucleico que lo codifica; vector de expresion recombinante; celula hospedadora; metodo de produccion del anticuerpo; composicion farmaceutica que lo comprende; y su uso para tratar el cancer.
NZ597664A (en) Humanized anti-cdcp1 antibodies
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20200511